Skip to main content

Table 3 Response to clinical scenarios

From: Cancer physicians’ attitude towards treatment of the elderly cancer patient in a developed Asian country

Scenario 1: Stage IV Diffuse Large B-cell Non-Hodgkin’s Lymphoma (n = 55)
Treatment options for the older patient Number Percentage
R-CHOP1 × 6 + Intrathecal Methotrexate 26 47%
R-CVP2 × 6 21 38%
CHOP3 × 6 4 7%
Palliative radiotherapy 3 6%
Best Supportive Care 1 2%
Treatment options for the younger patient Number Percentage
RCHOP × 6 + Intrathecal Methotrexate 45 82%
R-CVP × 6 7 13%
CHOP × 6 3 5%
Palliative radiotherapy 0 0%
Best Supportive Care 0 0%
Factors affecting treatment decision   
Performance Status 47 85%
Cancer type 37 67%
Cancer stage 20 36%
Patient decision 16 29%
Co-morbidities 15 27%
Age 14 25%
Scenario 2: Stage IIB, Node positive, Hormone receptor positive Breast cancer (n = 53)
Treatment options for the older patient Number Percentage
Aromatase inhibitor × 5 years 34 64%
Tamoxifen × 5 years 8 15%
AC4 × 4 → T5 × 12, then endocrine treatment 5 9%
CMF6 × 6, then endocrine treatment 1 2%
FAC7 × 6, then endocrine treatment 1 2%
Others 4 8%
Treatment options for younger patient Number Percentage
AC × 4 → T × 12, then endocrine treatment 44 83%
FAC × 6, then endocrine treatment 5 9%
CMF × 6, then endocrine treatment 2 4%
Others 2 4%
Aromatase inhibitor × 5 years 0 0%
Tamoxifen × 5 years 0 0%
Factors affecting treatment decision Number Percentage
Cancer Stage 38 72%
Cancer Type 32 60%
Performance Status 25 47%
Age 24 45%
Patient decision 16 30%
Co-morbidities 9 17%
  1. 1R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; 2R-CVP: Rituximab, Cyclophosphamide, Vincristine and Prednisolone; 3CHOP: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; 4 AC: Doxorubicin and Cyclophosphamide; 5 T: Paclitaxel; 6CMF: Cyclophosphamide, Methotrexate and 5 Fluorouracil; 7FAC: 5 Flurouracil, Doxorubicin and Cyclophosphamide.
  2. Two and four surveys each were incomplete for scenario 1 and scenario 2. Four participants who were haematologists were not familiar with treatment of breast cancer and opted not to fill in the section of the survey pertaining to the case scenario for breast cancer. Similarly, two oncologists opted not to fill in the lymphoma case scenario as they had limited experience treating patients with lymphoma.